Innoviva, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Innoviva reported Q2 2026 total revenue of $119.6M (19% YoY growth), with IST net product sales of $51.8M (46% growth; $36.6M U.S., 26% growth). Royalty revenue from GSK stable at $59.8M. Company launched wholly-owned Nortiva Bio subsidiary for LYNX long-acting oral drug delivery platform. Strategic healthcare investments valued at $669.5M (down from fair value losses, primarily $161M Armata Pharmaceuticals decline). Net loss of $83.4M ($1.14 per share) driven by investment fair-value decreases, not operations. Operating income $50.9M. Cash $570.4M. Repurchased 1.4M shares for $31.4M in Q2; $56.4M total under $125M program.
Why this rating
Strong operational growth (46% IST sales) and Nortiva launch offset by large mark-to-market investment losses. Growth meaningful but relative to $1.3B market cap; net loss accounting-driven, not operational. Routine business execution.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.